Company Description
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.
It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs.
In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
| Country | Canada |
| Founded | 2019 |
| IPO Date | May 11, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Clifford A. Starke |
Contact Details
Address: 3230 W. Commercial Boulevard, Suite 180 Fort Lauderdale, Florida 33309 United States | |
| Phone | 416-861-2267 |
| Website | floragrowth.com |
Stock Details
| Ticker Symbol | FLGC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001790169 |
| CUSIP Number | 339764102 |
| ISIN Number | CA3397642016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Clifford A. Starke | Chief Executive Officer and Director |
| Dany Vaiman | Chief Financial Officer |
| Aaron Atin | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 21, 2024 | PRER14A | Filing |
| Jun 5, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 8-K/A | [Amend] Current report |
| May 31, 2024 | ARS | Filing |
| May 31, 2024 | PRE 14A | Other preliminary proxy statements |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| May 6, 2024 | 8-K | Current Report |